确定成人型弥漫性胶质瘤患者的静脉血栓栓塞风险
研究分析258例新诊断WHO 2–4级成人型弥漫性胶质瘤患者的术前动脉血、肿瘤组织及临床病理数据,46例(17.8%)发生静脉血栓栓塞(VTE)。组织因子和podoplanin表达与VTE正相关,IDH突变通过抑制组织因子降低VTE风险;基于10个变量构建的在线VTE预测工具在2个外部队列中验证。
要点
- 258例成人型弥漫性胶质瘤中46例(17.8%)发生VTE。
- 肿瘤组织因子和podoplanin表达均与VTE正相关,但循环中仅组织因子和D-二聚体与VTE风险相关。
- IDH1/IDH2突变者VTE较少,多变量分析提示源于IDH突变抑制组织因子而非podoplanin。
核心结论
- 研究构建了基于10个变量的在线VTE预测工具,并在其他机构的2个成人型弥漫性胶质瘤患者队列中验证,为临床医生降低胶质瘤患者VTE风险提供循证指导。
研究设计与样本
- 分析258例新诊断WHO 2–4级成人型弥漫性胶质瘤患者的术前动脉血、肿瘤组织及临床病理数据(包括下一代测序数据)。
主要发现
- 46例(17.8%)发生VTE。
- 肿瘤组织因子和podoplanin表达均与VTE正相关,但循环中仅组织因子和D-二聚体与VTE风险相关,循环podoplanin与VTE风险不相关。
- IDH1或IDH2突变(IDHmut)的胶质瘤引起较少的VTE;多变量分析提示这是由于IDHmut抑制组织因子而非podoplanin。
- 预测时间-事件模型显示以下因素预测新诊断胶质瘤患者VTE风险增加:VTE病史、高血压、哮喘、白细胞计数、WHO肿瘤分级、患者年龄和体重指数;相反,IDHmut、甲状腺功能减退和MGMT启动子甲基化预测VTE风险降低。
关键数值与推荐
- 10个变量用于创建在线VTE预测工具:VTE病史、高血压、哮喘、白细胞计数、WHO肿瘤分级、患者年龄、体重指数、IDHmut、甲状腺功能减退、MGMT启动子甲基化。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Venous thromboembolism (VTE) is a life-threating condition that is common in patients with adult-type diffuse gliomas, yet thromboprophylaxis is controversial because of possible intracerebral hemorrhage. Effective VTE prediction models exist for other cancers, but not glioma. Our objective was to develop a VTE prediction tool to improve glioma patient care, incorporating clinical, blood-based, histologic, and molecular markers. We analyzed preoperative arterial blood, tumor tissue, and clinical-pathologic data (including next-generation sequencing data) from 258 patients with newly diagnosed World Health Organization (WHO) grade 2 to 4 adult-type diffuse gliomas. Forty-six (17.8%) experienced VTE. Tumor expression of tissue factor (TF) and podoplanin (PDPN) each positively correlated with VTE, although only circulating TF and D-dimers, not circulating PDPN, correlated with VTE risk. Gliomas with mutations in isocitrate dehydrogenase 1 (IDH1) or IDH2 (IDHmut) caused fewer VTEs; multivariable analysis suggested that this is due to IDHmut suppression of TF, not PDPN. In a predictive time-to-event model, the following predicted increased VTE risk in newly diagnosed patients with glioma: (1) history of VTE; (2) hypertension; (3) asthma; (4) white blood cell count; (5) WHO tumor grade; (6) patient age; and (7) body mass index. Conversely, IDHmut, hypothyroidism, and MGMT promoter methylation predicted reduced VTE risk. These 10 variables were used to create a web-based VTE prediction tool that was validated in 2 separate cohorts of patients with adult-type diffuse glioma from other institutions. This study extends our understanding of the VTE landscape in these tumors and provides evidence-based guidance for clinicians to mitigate VTE risk in patients with glioma.
引用
- Burdett KB, Unruh D, Drumm M, et al. Determining venous thromboembolism risk in patients with adult-type diffuse glioma. Blood. 2023. PMID: 36399711. doi:10.1182/blood.2022017858
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。